Quiver Bioscience ("Quiver"), a discovery platform, technology and therapeutics company advancing programs for the treatment ...

HAMBURG and MARBURG, GERMANY / ACCESSWIRE / August 5, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the leading independent European antisense drug discovery ...

Eight Northwestern researchers published a study April 29 detailing how RNA therapy could be used before birth to combat a ...

An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...

Patients treated with high-dose BIIB080 saw positive trends on the global Clinical Dementia Rating Sum of Boxes, Mini-Mental State Exam cognitive scales and Functional Activities Questionnaire at week ...

Isis Pharmaceuticals announced the presentation of data from its clinical trials of ISIS 113715 and ISIS-GCGRRx for the treatment of diabetes. In a Phase 2 study, ISIS 113715 demonstrated improvements ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

In Phase 1 trial, tau antisense therapy appeared safe. BIIB080 lowered CSF tau levels by 30 to 50 percent. Phase 2 planned to start next year. “This is a landmark study of human tau therapeutics,” ...

Scientists at St. Jude Children's Research Hospital have found that they can reverse the effects of HNRNPH2-related ...

TMDU researchers demonstrate proof of concept of antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. Parkinson's disease (PD), as well as many other ...

An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical Center ...